Viking Therapeutics (NASDAQ:VKTX) Earns Outperform Rating from Analysts at Citigroup
Citigroup initiated coverage on shares of Viking Therapeutics (NASDAQ:VKTX) in a report published on Monday, The Fly reports. The brokerage issued an outperform rating on the biotechnology company’s stock.
A number of other equities research analysts also recently weighed in on the stock. Svb Leerink raised shares of Viking Therapeutics from a market perform rating to an outperform rating and boosted their price target for the stock from $10.00 to $21.00 in a research note on Friday, March 29th. Stifel Nicolaus started coverage on shares of GENFIT S A/ADR in a research note on Tuesday, June 25th. They set a hold rating for the company. Leerink Swann raised shares of Viking Therapeutics from a market perform rating to an outperform rating and set a $8.86 price target for the company in a research note on Friday, March 29th. BidaskClub downgraded shares of Extraction Oil & Gas from a hold rating to a sell rating in a research note on Saturday, May 4th. Finally, William Blair reissued an outperform rating on shares of Accenture in a research note on Friday, March 29th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of Buy and a consensus target price of $20.53.
VKTX opened at $8.25 on Monday. The company has a market capitalization of $593.67 million, a P/E ratio of -20.63 and a beta of 2.30. The business’s 50 day simple moving average is $8.07. Viking Therapeutics has a fifty-two week low of $6.97 and a fifty-two week high of $24.00.
Large investors have recently modified their holdings of the business. Great West Life Assurance Co. Can bought a new stake in Viking Therapeutics in the fourth quarter valued at approximately $53,000. Legal & General Group Plc increased its stake in Viking Therapeutics by 38.0% in the fourth quarter. Legal & General Group Plc now owns 10,704 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 2,945 shares in the last quarter. United Services Automobile Association bought a new stake in Viking Therapeutics in the fourth quarter valued at approximately $83,000. Barclays PLC increased its stake in Viking Therapeutics by 114.7% in the fourth quarter. Barclays PLC now owns 11,647 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 91,118 shares in the last quarter. Finally, BNP Paribas Arbitrage SA bought a new stake in Viking Therapeutics in the first quarter valued at approximately $126,000. 63.53% of the stock is owned by hedge funds and other institutional investors.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
See Also: What are convertible shares?
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.